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Abstract
Background: The COVID-19 pandemic is caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2). At the time of writing, neither a cure nor a vaccine has
been approved by the World health organization (WHO) for this disease. Given the
fact that the severe acute respiratory syndrome coronavirus (SARS) and Middle East
Respiratory Syndrome (MERS) viruses have a genetic sequencing similar to SARS-CoV-
2, and since the use of convalescent plasma therapy (CP) has proved its efficacy in
SARS and MERS virus infections, researchers are starting to focus more on it as a
possible therapy for the COVID-19 disease. The main objective of this rapid review is
to report and summarize the published evidence on the role of convalescent plasma
therapy in the current COVID-19 pandemic.
Method: The PICO method was used to establish the review question. Moreover,
papers were gathered from PubMed and Google scholar, critically appraised for the
best evidence. Piersons 5-component scheme was used to check the quality of the
review papers.
Results: After website screening: 10 papers in PubMed and 6 papers from Google
scholars were retrieved. There were encouraging reports regarding the uses of CP
in the previous viral outbreaks likes SARS and Ebola, yet there is still a doubt on the
efficacy of this mode of therapy in the current COVID-19 pandemic.
Conclusion: CP is a very promising treatment approach for COVID-19 patients;
however, more clinical trials are required to validate the effectiveness of this therapy.
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1. Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), originating fromWuhan
in China, has rapidly enveloped the world becoming a pandemic [1]. As of the 13th of
April,2020, there were 1,773,084 worldwide confirmed cases with 111,652 deaths as
reported by the world health organization (WHO) [2]. The virus sequencing revealed a
high similarity to SARS, making it the seventh virus discovered of this family. On the 11th
of February, 2020, theWHOofficially named the disease caused by this virus, COVID-19.
Many trials have assessed possible therapeutics and prevention methods for the
disease. Nonetheless, to date, there are no drugs or vaccines specifically approved
for the disease by the WHO [3]. Options of treatment such as antiviral drugs and
corticosteroids are still under review by many agencies and are yet to be officially
approved by the WHO [3, 4].
Serology testing of COVID-19 patients has revealed a notable rise in IgM antibodies in
the acute setting, followed by rise in IgG antibodies as the patient entered the recovery
phase. Therefore, many researchers have suggested using convalescent plasma from
the recovered patient, and applying it as a passive antibody therapy for severe COVID-
19 patients [5, 6]. Specific application of plasma therapy was similarly used during
the EBOLA virus pandemic in 2014, when the WHO officially authorized the use of
convalescent plasma as an empirical treatment therapy and published guidelines that
specify the steps for donor selection, specimen collection and administration of this
therapy to the Ebola infected patients [7]. Convalescent plasma therapy was also used
successfully in managing diseases, caused by influenza virus and other pathogens [8, 9].
Closely related to the use of convalescent plasma therapy, is the use of monoclonal
antibodies. The therapeutic potential of this mode of treatment has proved effective in
the past in the treatment of many diseases. Some studies tested the effectiveness of
monoclonal antibodies in vitro and in vivo against viral infections like SARS and MERS
and they were found to yield positive results, yet like other types of treatment modalities,
more clinical trials are needed to confirm the effectiveness of this method in the context
of COVID-19 patients [10, 11].
When the patient is infected with a virus, his immune system starts to produce
antibodies against the virus, which can later be harnessed in the form of convalescent
plasma and transfused into a patient with a current infection, where it can neutralize and
even induce antibody-dependent cellular cytotoxicity against the invading virus. This
approach is usually used in conjunction with other antiviral and maintenance therapy
[5, 12–16]. Mechanisms of convalescent plasma therapy illustrated in Fig 1.
CP therapy has been applied in clinical practice for a long time but its efficacy remains
a point of debate between health professionals. Previous research proved this technique
useful in the case of SARS1 and MERS infections, and since SARS-COV2 and SARS-
COV1 and MERS viruses share clinical and genetic similarities, it is predicted that this
type of therapy will have a good result in COVID-19 patients. Yet, some reports doubted
the efficiency of this maneuver as the plasma will not be pure, and it may even contain
other viral particles, which may cause patients to contact other diseases [17–19].
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Figure 1: Mechanisms of convalescent plasma therapy (This image was created by author Mujahed I.
Mustafa)
However, using antivirals may not be a cost-e ffective method for treatment in low
income countries like Sudan, whereas plasma therapy extraction and preparation are
more readily available and achievable in these countries making it a more reasonable
choice of therapy [20]. The main objective of this rapid review is to clarify the conflicting
evidence regarding the use of convalescent plasma therapy in COVID-19 patients, and
to summarize the best evidence available.
2. Method
On the 10th of April 2020 the research databases PubMed, Google Scholar were
screened for articles providing information on the use of convalescent plasma for the
treatment of COVID-19 patients, (Fig.2). The inclusion criteria were any published (full
text) articles written in English and all clinical study designs including case series.
Furthermore, any articles published before 2019, and articles with no significant or
duplicated information were excluded. Subsequently, reference lists of identified articles
were searched to extract further relevant articles. Two reviewers conducted a detailed
screening of the titles and abstracts. All authors independently performed full-text
screening of identified articles and participated in the steps of manuscript preparation,
writing and final revision. The PICO method was used to establish the review question
in a standardized form (Table 1). The quality of each clinical report study was evaluated
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using Piersons 5-component scheme, which composes of the following five components
each with a score of zero to one (uniqueness, documentation, interpretation, objectivity,
and educational value) with scores of 5 or less indicate of insufficient quality [21]
2.1. Data synthesis
The results were presented in a narrative format as the heterogeneity of outcomes and
study designs made quantitative synthesis inappropriate.
TABLE 1: PICOS items: formation of the review question.
PICOS item Description
Population Patients with laboratory-confirmed SARS-COV-2 infection.
Intervention Convalescent plasma therapy
Comparisons Patients with COVID-19 disease who did not receive CP transfusion.
Outcome Clinical outcomes of SARS-CoV-2 infection including but not limited to
death, intensive care admission, ventilation, and SARS-CoV-2 viral
shedding.
3. Results
A total of 16 articles were found after preliminary screening of the PubMed and Google
Scholars databases. After title and abstract screening, a total of 9 articles were excluded.
Full-text screening of the remaining 7 articles was conducted. Among these studies, after
critical appraisal full-text screening, a total of 4 articles were included in the final review,
all were published in respected journals. Three articles were excluded after full-text
screen (1 review article, 1 letter to the editor, and 1one commentary) Fig 2. Details of
studies included in this review are summarized in Table 2.
Pierson’s assessment showed that the article produced by Duan et al [5] was the
highest quality report with a score of 9 in comparison to only 8 in the other three
reports (Shen et al [22],Jy Ahn et al [23],and Zhang et al [24]).
4. Discussion
Currently antiviral medication Remdesivir along with other antiviral drugs hold promising
results in the fight against COVID-19. However, factors such as the high price and the
unavailability of these medications in low resource setting countries coupled with the
long time period needed to develop and test a vaccine (12 to 18 moths) [17], these factors
make these medications inappropriate choices in low resource settings like Sudan and
other similar countries. Therefore, searching for more reasonable treatment choices like
convalesce plasma therapy [13], is appropriate since most countries already have the
infrastructure, needed to prepare and perform this type of therapy.
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Figure 2: Flow-gram of search and selection of articles
4.1. The use of convalescent plasma against SARS-CoV-2
Plasma treatment is an old method of therapy that can be traced back for more than a
century ago [14]. Furthermore, there are several examples where convalescent plasma
has been used successfully as a treatment of infectious diseases like SARS, MERS, H1N1,
H5N1 and Ebola. During SARS outbreak, patients who were treated with Plasma had
more favorable prognosis and fewer side effects than those treated with antiviral drugs
[25-32]. The largest study enrolled 80 patients in Hong Kong with SARS1. The patients
who received treatment before day 14 had better outcomes as defined by the release
from hospital before day 22 [28]. In comparison fewer studies were done in MERS
outbreak possibly due to the limited numbers of donors [17]. In this current pandemic
of SARS-CoV-2, several studies with limited data suggested that convalescent plasma
is beneficial in extremely severe COVID-19 patients [5, 22-24].
Duan et al [5] in Wuhan performed a pilot study to explore the feasibility of CP
treatment in 10 severe COVID-19 patients. 200 ml of convalescent plasma derived from
recovered donors was transfused to the patients with neutralizing antibody titers more
than 1:640. The patients were receiving maximal supportive treatment and antiviral
therapy. After the transfusion, the neutralizing antibody titer was raised to 1:640 in five
cases and maintained at a high level (1:640) in four cases. The clinical outcome showed
dramatic improvement of symptoms within 1 to 3 days, and improved oxygen saturation
within 3 days. Laboratory parameters also improved, the mean lymphocyte counts were
raised from (0.65× 109/L) to (0.76× 109/L) and themean C-reactive protein declined from
(55.98 mg/L) to (18.13 mg/L). Radiological Imaging showed varying degrees of reduction
of pulmonary lesions within 7 days. The viral load was undetectable in seven patients
after transfusion who had previous viremia. No severe adverse effects were detected.
The dose mention here is close to the therapeutic dose of 250 ml, recommended
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in a review by Evan M. Bloch and colleagues [7]. Nevertheless, the optimal dose and
treatment duration, as well as the clinical benefit of CP therapy need further investigation
in larger well-controlled trials.
In addition, Shen et al [22] in Shenzhen, China, assessed the initial clinical experience
with convalescent plasma transfusion administered to critically ill patients with COVID-
19. The study involved five critically ill patients on mechanical. The patients were
receiving antiviral treatment and methylprednisolone. Following convalescent plasma
transfusion, the patients’ body temperature improved in 4 out of 5 patients within three
days. The SOFA (Sequential Organ Failure Assessment score) declined from (2-10)
before transfusion to (1- 4) 12 days after the transfusion. The PAO2/FIO2 ratio was raised
from (172-276) to (284-366) after 12 days, and the viral load became undetectable within
the same period. The neutralizing antibody titers were raised from (40-60) to (80-320)
on the seventh day after the transfusion. Within 2 weeks, four patients recovered from
ARDS (Acute Respiratory Distress Syndrome), and three patients were weaned from
mechanical ventilators. Two out of five patients were stable at 37 days, and three have
been discharged within 2 months. These preliminary outcomes raise the probability
that convalescent plasma transfusion may be supportive in the treatment of critically ill
patients with COVID-19.
In Korea, JY Ahn et al [23] reported two cases of severe COVID-19 patients presenting
acute respiratory distress syndrome (ARDS), who showed a favorable clinical course
after the convalescent plasma infusion. In the first patient the fever normalized and
oxygen demand declined one day after the transfusion. The patient’s condition was
much improved with decreased CRP and IL-6 to normal levels. After 8 days PaO2/FiO2
ratio became normal. Chest X-ray revealed disappearance of lung lesions after 3 days.
The virus was undetectable after day 26. The patient had tracheostomy and was
successfully weaned from mechanical ventilation. In the second case, Leukocytosis and
lymphopenia recovered immediately after plasma transfusion. The density of pulmonary
infiltrates on chest X-ray much improved 3 days after transfusion with increase in the
PaO2/FiO2 ratio to 230. The level of CRP and IL-6 also normalized. SARS-CoV-2 was
undetectable after day 20, and the patient was discharged on day 24.
This rapid improvement waswitnessed again in a study done by Zhang et al [24]. They
report the disease course on four critically ill patients infected with SARS-CoV-2 and
treated with supportive care and convalescent plasma. They were confirmed positive by
reverse transcriptase PCR. All of them received antiviral therapy and other supportive
measures. The four patients developed ARDS during the first week of admission, and 3
of them received invasive ventilation. Three out of four developed septic shock, and 2
of them deteriorated to multi organ failure who received continuous renal replacement
therapy (CRRT) and veno-venous extracorporeal membrane oxygenation (ECMO). The
4 patients received different doses of plasma therapy (900ml, 200 ml, 2400ml and 300
ml) respectively. The four patients showed resolution of the chest radiograph lesions.
The RT PCR became negative within 4 days of plasma infusion in 3 patients and within
3 weeks in the fourth patient. The 4 patients were discharged from the ICU at (14, 7, 10,
27) days of plasma transfusion. The difference in the time of recovery between these
groups of patients could be attributed to the difference in the doses and duration of
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convalescent plasma used in these studies among other possible reasons. Furthermore,
the absence of severe side effects in these reports supports the safety profile of this
mode of therapy, although amore prolonged clinical trials are needed to confirm these
results.
This improvement in patient condition and decrease in hospital stays are equivalent
to what was noticed in the use of convalescent plasma therapy in SARS patients in
2004 in a retrospective study done by Soo Yo et al. Where they compare the clinical
outcomes between two groups of SARS patients, one group on methyl prednisolone
and the other on convalescent plasma, in which they reported a shorter hospital stay
(p 0.001) and lower mortality (p 0.049) in the group receiving the plasma therapy [28].
The common factors in these four studies are the clinical benefit of convalescent
plasma therapy and the very limited number of participants, which necessitates further
investigation in larger well-controlled trials.
Despite the rapid improvement witnessed in these patients, animal studies in SARS
COV virus, sometimes show an aggravation of clinical symptoms despite the reduction in
viral load, possibly due to the role of passive plasma antibodies in shifting the burden of
infections to macrophage which potentiates the dysregulated immune response against
the virus [33].
4.2. Donor Eligibility
Zhang Dingyu, the director of Wuhan Jinyintan Hospital, has stated that to be a donor
you have to be between 18 and 55 years old, and to have recovered for at least 14 days
before blood donation. If the person is in good health, the age range cloud is extended
to up 60 years old.
Before donation, the donor has to screen for relevant transfusion-transmitted infec-
tions such as HIV, syphilis, Hepatitis B and C [34, 35].
4.3. Patient Eligibility
• Laboratory confirmed the COVID-19 status of the patient by RT-PCR.
• Severe or immediately life-threatening COVID-19. severe disease is defined as
showing one or more of the following: shortness of breath, respiratory frequency
≥ 30/min, blood oxygen saturation ≤ 93%, the partial pressure of arterial oxygen
to fraction of inspired oxygen ratio < 300, lung infiltrates > 50% within 24 to 48
hours.
The life-threatening disease is defined by the occurrence of one or more of the
following: respiratory failure, septic shock and multiple organ failure.
• Informed consent provided by the patient who will receive the therapy [35].
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4.4. Preparation of convalescent Plasma in low resource setting
The protocol for plasma preparation differs between countries but usually it contains
two major parts: the first is the donor selection, which was previously mentioned; and
the second is plasma preparations.
The plasma preparations start by separation the plasma from the blood by Plasma
apheresis device or any other simple extraction methods (well within the remit of most
blood banks) and then checking the antibodies level in the plasma by the enzyme-
linked immunosorbent assay (ELISA). (In addition, checking and inactivation of the viral
load will be undertaken to decrease the possibility of transmitting infection). And finally,
freezing the plasma and storing it in aliquots of around 300ml [36]. These steps are
summarized in Figure 3.
4.5. Convalescent Plasma Therapy Limitations
Although being a relatively available method of treatment yet, the recovered patients
have to wait at least 14 days before they can donate their blood. Furthermore, the
dose has to be high enough to be effective, as it was noticed in the clinical trials
of convalescence plasma in MERS-CoV Infection, Saudi Arabia [17]. Other practical
concerns in plasma donation may include difficulties in reaching the recovered patients
by phone and the refusal of voluntary involvement in the donation [37].
Figure 3: flow chart of convalescent plasma preparation in covid-19 patients showing the major steps from
donor selection to the administration of screened plasma units. PCR: Polymerase chain reaction. ELISA:
enzyme-linked immunosorbent assay
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5. Conclusion
In summary, this rapid review shows a potential therapeutic effect of convalescent
plasma in the treatment of COVID-19 patients. This is due to the fact that all the laboratory
investigations come back to normal, as well as the clinical outcome, showed a dramatic
improvement of symptoms within 1 to 3 days following convalescent plasma transfusion.
Though convalescent plasma therapy has not yet been approved as a treatment for
COVID-19 disease, there is growing evidence of its effectiveness in the previous SARS
and MERS infection. Hence, we recommend plasma therapy to be used as treatment
in the current COVID-19 pandemic in the form of clinical trials, especially in areas with
low resource setting such as Sudan.
6. Limitations of the Reviewed Evidence
Several clinical trials reported enrolling small number of patients, which will be poorly
representative of the general population, and hence it will be difficult to generalize the
results of these studies. Another problem is the lack of long follow-up, which means that
we are lacking the knowledge of the possible long side effects of this therapy [15, 16].
7. Strength and Limitations of the Current Paper
To our knowledge, this is the first rapid review, reporting the available evidence regard-
ing the effectiveness and safety of convalescent plasma therapy in COVID-19 patients in
low resource setting countries. In our attempt to spread the knowledge in a timely man-
ner, we rapidly conducted this review in a duration of 14 days without strict adherence
to systemic reviews guideline. Yet, we made sure that all reports used are published
in well-respected journals and hence we believe this review will provide an invaluable
asset in the fight against COVID-19 pandemic.
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